Pharma Stock Jumps After Receiving Approval for 2 Cancer-Related Bone Medicines

Synopsis: Biocon Limited received Health Canada approval for Bosaya™ and Vevzuo™, denosumab biosimilars for osteoporosis and cancer-related bone conditions, expanding global reach and affordable treatment options.

This Mid-Cap Pharma Stock, engaged in developing biopharmaceuticals, biosimilars, generics, and research services, focusing on diabetes, oncology, and immunology, and providing affordable healthcare solutions globally, jumped 1.70 percent after receiving two medicine approvals from Health Canada.

With a market capitalization of Rs. 58,693.07 crores, the share of Biocon Limited has reached an intraday high of Rs. 364.60 per equity share, rising nearly 1.70 percent from its previous day’s close price of Rs. 358.50. Since then, the stock has retreated and is currently trading at Rs. 362.10 per equity share. 

What is the News?

Biocon Limited has received approval from Health Canada for two new medicines, Bosaya™ and Vevzuo™, which are biosimilars of well-known drugs Prolia® and Xgeva®. These medicines are based on denosumab and are used to treat bone-related conditions. The approval allows Biocon to expand its presence in global markets and provide more affordable treatment options.

These medicines can help patients suffering from osteoporosis, a condition that weakens bones, and also support cancer patients who face bone complications. They are expected to benefit millions of people, especially older adults and patients with advanced cancer.

Bosaya™ is mainly used to increase bone strength in people at high risk of fractures, including women after menopause and patients undergoing certain cancer treatments. Vevzuo™ is used to reduce bone-related problems in cancer patients and treat rare bone tumors.

This approval is based on strong clinical data showing that both drugs are safe and effective, similar to the original medicines. It also highlights Biocon’s focus on innovation and affordable healthcare solutions.

Business Highlights:

Biocon Limited has built a strong global presence with over 47 years of experience and operations across more than 120 countries. The company operates 11 manufacturing locations and serves more than 1,500 patients, highlighting its wide reach and impact in the healthcare sector.

Biocon also has a strong scientific base with a team of over 5,600 scientists, including around 550 PhDs. It is among India’s most scaled CRDMO players with a bioreactor capacity of over 50 KL and serves around 400 active clients, including 14 of the top 20 global pharmaceutical companies.

Revenue Mix (Q4 FY26):

Biocon Limited reported total revenue of Rs. 4,173 crore in Q3 FY26. Biosimilars led with Rs. 2,497 crore, contributing around 59.8 percent of total revenue. The CRDMO segment added Rs. 917 crore (about 22.0 percent), while generics contributed Rs. 851 crore (around 20.4 percent). This mix highlights the company’s strong focus on biosimilars and growing contribution from research and manufacturing services.

Company Overview:

Biocon Limited was founded in 1978 and is an Indian biopharmaceutical company headquartered in Bengaluru, Karnataka. It develops, manufactures, and markets innovative and affordable biopharmaceuticals for chronic diseases such as diabetes, cancer, and autoimmune conditions. Founded by entrepreneur Kiran Mazumdar-Shaw, Biocon is one of India’s largest biotechnology firms and a key global supplier of biosimilars and biologics.

Recent Quarter Results:

Coming into financial highlights, Biocon Limited’s revenue has increased from Rs. 3,821 crore in Q3 FY25 to Rs. 4,173 crore in Q3 FY26, which has grown by 9.21 percent. The net profit of the company converted from positive to negative, from a net profit of Rs. 81 crore in Q3 FY25 to a net loss of Rs. 52 crore in Q3 FY26.

Biocon Limited’s revenue and net profit have grown at a CAGR of 23.09 percent and 22.78 percent, respectively, over the last three years.

In terms of return ratios, the company’s ROCE and ROE stand at 6.25 percent and 4.76 percent, respectively. Biocon Limited has an earnings per share (EPS) of Rs. 4.81, and its debt-to-equity ratio is 0.62x.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock Jumps After Receiving Approval for 2 Cancer-Related Bone Medicines appeared first on Trade Brains.